OBJECTIVES: The aim of this study was to estimate the cost per responder in the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension for latanoprostene bunod (LBN) compared to other prostaglandin analogs (PGAs) from a Canadian perspective.

METHODS: The cost per responder for each PGA was calculated by dividing the drug acquisition cost with its response rate. The response rate was defined by the percentage of patients with a ≥20% reduction in IOP at 3 months for each PGA and was obtained from a previous network meta-analysis, using a computer simulation technique. The analysis was performed from two different perspectives: a public payer perspective, where the cost was defined by using the generic prices when available, and from a societal perspective, where a weighted average cost was calculated based on the brand/generic split of Canadian claims. The estimated treatment duration for a bottle of 2.5 mL and 5 mL was assumed to be 21 days and 42 days, respectively. Treatment acquisition costs were obtained from the Ontario Drug Benefit Formulary and IQVIA.

RESULTS: From a public payer perspective, LBN is associated with a cost per responder of $92.03 and is ranked third after latanoprost ($61.63) and travoprost ($76.18), which are two PGAs that are genericized. From a societal perspective, LBN showed the lowest cost per responder at $92.03, followed by latanoprost at $97.71, travoprost at $100.07, and bimatoprost 0.03% and 0.01% at $158.29 and $211.52, respectively. When calculating the cost per non-responder, LBN cost was much lower at $545.89 than the other branded PGAs, bimatoprost 0.01% and 0.03% at $1,234 and $1,071, respectively.

CONCLUSIONS: LBN is associated with a favourable cost per responder and cost per non-responder compared to other PGAs available in Canada to reduce IOP in patients with OAG or ocular hypertension.